001     127605
005     20240228135030.0
024 7 _ |a 10.1016/j.radonc.2014.11.013
|2 doi
024 7 _ |a pmid:25465729
|2 pmid
024 7 _ |a 0167-8140
|2 ISSN
024 7 _ |a 1879-0887
|2 ISSN
037 _ _ |a DKFZ-2017-03628
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Koerber, Stefan Alexander
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a Influence of human papillomavirus and p16(INK4a) on treatment outcome of patients with anal cancer.
260 _ _ |a Amsterdam [u.a.]
|c 2014
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1522932009_31809
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The purpose of this study was to evaluate HPV-DNA and p16(INK4a) (p16) expression as prognostic markers for outcome in patients with anal cancer.From January 2000 to December 2011 a cohort of 105 anal cancer patients was treated with definitive chemoradiation at our institution. Tumor biopsies from 90 patients were analyzed for HPV-DNA by polymerase chain reaction and for p16 expression by immunohistochemistry.Median follow-up was 48.6months (range 2.8-169.1months). HPV-DNA or p16-expression was found in 75 anal cancers each (83.3%), concordance was detectable in 70 tumors (77.8%). Significantly improved overall survival (OS) [77.1% vs. 51.4%, p=0.005], progression-free survival (PFS) [64.0% vs. 35.0%, p<0.001] and improved local control [81.0% vs. 55.9%, p=0.023] was found for concomitant HPV- and p16-positive anal carcinomas (cHPPAC) in univariate analysis. Multivariate analysis showed better OS [p=0.015] and PFS [p=0.002] for cHPPAC.The combination of HPV-DNA and p16 can be used as an independent prognostic parameter in anal cancer patients.
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Biomarkers, Tumor
|2 NLM Chemicals
650 _ 7 |a Cyclin-Dependent Kinase Inhibitor p16
|2 NLM Chemicals
700 1 _ |a Schoneweg, Clara
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Slynko, Alla
|0 P:(DE-He78)4169c43af2de6fae487c89fc2e7cfaa8
|b 2
700 1 _ |a Krug, David
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Haefner, Matthias F
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Herfarth, Klaus
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Debus, Juergen
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Sterzing, Florian
|0 P:(DE-He78)75d45845a04db67c5a88db1086046ef1
|b 7
700 1 _ |a von Knebel Doeberitz, Magnus
|0 P:(DE-He78)11747cd1dc061b9333c0e3a3ff31bf2f
|b 8
700 1 _ |a Prigge, Elena-Sophie
|0 P:(DE-He78)83e1d0ede46be662d4a75f18e2dc7eec
|b 9
700 1 _ |a Reuschenbach, Miriam
|0 P:(DE-He78)143aa3fb27761522adf5909af9a5fd26
|b 10
|e Last author
773 _ _ |a 10.1016/j.radonc.2014.11.013
|g Vol. 113, no. 3, p. 331 - 336
|0 PERI:(DE-600)1500707-8
|n 3
|p 331 - 336
|t Radiotherapy and oncology
|v 113
|y 2014
|x 0167-8140
909 C O |p VDB
|o oai:inrepo02.dkfz.de:127605
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)4169c43af2de6fae487c89fc2e7cfaa8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)75d45845a04db67c5a88db1086046ef1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)11747cd1dc061b9333c0e3a3ff31bf2f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)83e1d0ede46be662d4a75f18e2dc7eec
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)143aa3fb27761522adf5909af9a5fd26
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|2 G:(DE-HGF)POF3-300
|v Translational cancer research
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2014
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b RADIOTHER ONCOL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)E050-20160331
|k E050
|l KKE Strahlentherapie
|x 0
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 1
920 1 _ |0 I:(DE-He78)G105-20160331
|k G105
|l Gentherapie von Tumoren
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E050-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)G105-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21